SSL tight-lipped over possible medical sale to VC (venture capital) firm
This article was originally published in Clinica
Executive Summary
SSL International has refused to comment on reports that venture capital firm 3i has outbid rivals Morgan Stanley Capital Partners and Apax Partners in a contest for a part of the UK firm's medical division. Sources close to the negotiations have confirmed the names of the final three bidders and 3i told Clinica it was "in active discussions with the company". Rumour has it that the surgical glove and antiseptics business could be sold for as much as £250-275m ($425-470m).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.